Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$10.87 -5.3%	$8.82	$4.93 ▼ $14.44	$980.07M	0.72	1.19 million shs	1.06 million shs
LCTX Lineage Cell Therapeutics	$1.00 -6.5%	$0.77	$0.37 ▼ $1.15	$244.34M	1.6	1.62 million shs	1.38 million shs
LENZ LENZ Therapeutics	$32.75 -2.9%	$29.78	$16.54 ▼ $38.93	$949.37M	0.42	196,637 shs	462,639 shs
ORIC Oric Pharmaceuticals	$10.98 +1.2%	$8.45	$3.90 ▼ $14.67	$924.68M	1.54	786,573 shs	467,182 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	-5.31%	+6.67%	+35.37%	+22.96%	+86.45%
LCTX Lineage Cell Therapeutics	-6.54%	+1.53%	+23.38%	+139.92%	-0.99%
LENZ LENZ Therapeutics	-2.91%	+4.43%	+12.93%	+42.02%	+50.85%
ORIC Oric Pharmaceuticals	+1.20%	+5.27%	+14.02%	+134.12%	+2.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.8911 of 5 stars	3.7	1.0	4.7	2.5	0.8	0.6
LCTX Lineage Cell Therapeutics	2.0273 of 5 stars	3.5	1.0	0.0	0.6	3.3	0.6
LENZ LENZ Therapeutics	1.3305 of 5 stars	3.6	0.0	0.0	2.4	0.8	0.0
ORIC Oric Pharmaceuticals	4.5466 of 5 stars	4.5	1.0	4.4	2.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	304.78% Upside
LCTX Lineage Cell Therapeutics	3.00	Buy	$4.20	320.00% Upside
LENZ LENZ Therapeutics	3.17	Buy	$46.60	42.29% Upside
ORIC Oric Pharmaceuticals	3.00	Buy	$18.57	69.14% Upside

Current Analyst Ratings Breakdown

Latest LCTX, AVXL, ORIC, and LENZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	ORIC Oric Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/23/2025	LCTX Lineage Cell Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.00
6/23/2025	LCTX Lineage Cell Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/23/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/29/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/8/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
5/6/2025	ORIC Oric Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $12.00
5/6/2025	ORIC Oric Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/5/2025	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00
4/16/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
LCTX Lineage Cell Therapeutics	$9.50M	24.04	N/A	N/A	$0.35 per share	2.86
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$7.42 per share	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.45 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-40.93%	-36.38%	8/5/2025 (Estimated)
LCTX Lineage Cell Therapeutics	-$18.61M	-$0.12	N/A	N/A	N/A	-169.57%	-22.64%	-15.27%	8/6/2025 (Estimated)
LENZ LENZ Therapeutics	-$49.77M	-$1.77	N/A	N/A	N/A	N/A	-23.74%	-22.65%	8/13/2025 (Estimated)
ORIC Oric Pharmaceuticals	-$127.85M	-$1.87	N/A	N/A	N/A	N/A	-51.14%	-46.29%	8/11/2025 (Estimated)

Latest LCTX, AVXL, ORIC, and LENZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	LENZ LENZ Therapeutics	-$0.62	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ORIC Oric Pharmaceuticals	-$0.46	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q3 2025	AVXL Anavex Life Sciences	-$0.13	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/7/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
5/5/2025	Q1 2025	ORIC Oric Pharmaceuticals	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	6.74	6.74
LCTX Lineage Cell Therapeutics	N/A	3.82	3.82
LENZ LENZ Therapeutics	N/A	23.09	23.09
ORIC Oric Pharmaceuticals	N/A	12.00	12.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
LCTX Lineage Cell Therapeutics	62.47%
LENZ LENZ Therapeutics	54.32%
ORIC Oric Pharmaceuticals	95.05%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.00%
LCTX Lineage Cell Therapeutics	26.80%
LENZ LENZ Therapeutics	6.90%
ORIC Oric Pharmaceuticals	5.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.37 million	75.98 million	Optionable
LCTX Lineage Cell Therapeutics	60	228.36 million	167.16 million	Not Optionable
LENZ LENZ Therapeutics	110	28.15 million	26.20 million	N/A
ORIC Oric Pharmaceuticals	80	85.22 million	80.49 million	Optionable

LCTX, AVXL, ORIC, and LENZ Headlines

Recent News About These Companies

Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?

5 hours ago | finance.yahoo.com

Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock ... - Nasdaq

July 13 at 7:05 PM | nasdaq.com

Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?

July 11, 2025 | zacks.com

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9% - Here's What Happened

July 11, 2025 | marketbeat.com

Ladenburg Thalmann Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Buy Recommendation

July 9, 2025 | msn.com

Brokerages Set Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $19.17

July 9, 2025 | americanbankingnews.com

Oric Pharmaceuticals (NASDAQ:ORIC) Now Covered by LADENBURG THALM/SH SH

July 8, 2025 | marketbeat.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Recommendation of "Buy" from Analysts

July 6, 2025 | marketbeat.com

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 5, 2025 | morningstar.comM

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 3, 2025 | globenewswire.com

Metastatic Prostate Cancer Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

July 3, 2025 | theglobeandmail.com

Oric Pharmaceuticals (NASDAQ:ORIC) Trading 10% Higher - Time to Buy?

July 2, 2025 | marketbeat.com

Oric Pharmaceuticals Inc. Advanced Charts | ORIC | Barron's

June 28, 2025 | barrons.com

Oric Pharmaceuticals Shows Market Leadership With Jump To 93 RS Rating

June 25, 2025 | msn.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $10,340.00 in Stock

June 25, 2025 | insidertrades.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 1,034 Shares

June 24, 2025 | marketbeat.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $340,893.00 in Stock

June 24, 2025 | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up Following Insider Buying Activity

June 24, 2025 | marketbeat.com

Angie You Purchases 1,403 Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock

June 24, 2025 | insidertrades.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Angie You Acquires 26,597 Shares

June 23, 2025 | marketbeat.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Angie You Acquires 1,403 Shares

June 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
The Meteoric Rise of Rocket Lab: A Space Stock to Watch
By Ryan Hasson | July 11, 2025
View The Meteoric Rise of Rocket Lab: A Space Stock to Watch
Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
3 Infrastructure Stocks Riding the U.S. Building Boom
By Chris Markoch | July 14, 2025
View 3 Infrastructure Stocks Riding the U.S. Building Boom

LCTX, AVXL, ORIC, and LENZ Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$10.87 -0.61 (-5.31%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$10.90 +0.03 (+0.28%)

As of 07/15/2025 07:49 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$1.00 -0.07 (-6.54%)

Closing price 07/15/2025 04:10 PM Eastern

Extended Trading

$1.02 +0.02 (+2.50%)

As of 07/15/2025 07:55 PM Eastern

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

LENZ Therapeutics NASDAQ:LENZ

$32.75 -0.98 (-2.91%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$34.12 +1.37 (+4.18%)

As of 07/15/2025 06:34 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Oric Pharmaceuticals NASDAQ:ORIC

$10.98 +0.13 (+1.20%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$10.98 -0.01 (-0.05%)

As of 07/15/2025 06:40 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time